Antibodies have been used for more than 100 years in the therapy of infectious diseases,
but a new generation of highly potent and/or broadly cross-reactive human monoclonal …

Antibodies serve as critical barriers to viral infection. Humoral immunity to a virus is achieved
through the dual role of antibodies in communicating the presence of invading pathogens in …

SARS-CoV-2 has caused the COVID-19 pandemic. There is an urgent need for
physiological models to study SARS-CoV-2 infection using human disease-relevant cells …

There is an urgent need to create novel models using human disease-relevant cells to study
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) biology and to facilitate …

A central goal of HIV-1 vaccine research is the elicitation of antibodies capable of
neutralizing diverse primary isolates of HIV-1. Here we show that focusing the immune …

The recent Ebola virus (EBOV) epidemic highlighted the need for effective vaccines and
therapeutics to limit and prevent outbreaks. Host antibodies against EBOV are critical for …

Determinants of protective immunity against severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) infection require the development of well-standardized, reproducible …

Historically, emerging viruses appear constantly and have cost millions of human lives.
Currently, climate change and intense globalization have created favorable conditions for …

Antibodies are promising post-exposure therapies against emerging viruses, but which
antibody features and in vitro assays best forecast protection are unclear. Our international …

Ebola virus (EBOV) remains a public health threat. We performed a longitudinal study of B
cell responses to EBOV in four survivors of the 2014 West African outbreak. Infection …